DiaMedica Therapeutics (DMAC) Current Leases (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Current Leases for 9 consecutive years, with $107000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Leases rose 11.46% year-over-year to $107000.0; the trailing twelve-month figure through Jun 2026 stood at $107000.0 (up 11.46% YoY), and the FY2025 full-year result was $101000.0, up 12.22% from the prior year.
• Current Leases improved to $107000.0 in Q2 2026 per DMAC's latest filing, from $104000.0 in the prior quarter.
• Across five years, Current Leases topped out at $107000.0 in Q2 2026 and bottomed at $11000.0 in Q2 2022.
• Historically, Current Leases has averaged $77166.7 across 5 years, with a median of $84000.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Current Leases tumbled 82.81% in 2022, then jumped 590.91% in 2023.
• Over 5 years, Current Leases stood at $63000.0 in 2022, then climbed by 26.98% to $80000.0 in 2023, then gained by 12.5% to $90000.0 in 2024, then gained by 12.22% to $101000.0 in 2025, then advanced by 5.94% to $107000.0 in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $107000.0, $104000.0, and $101000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.